Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02711345 · OUTCOME

Percentage of Participants With at Least One Dose Interruptions

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. · Source last updated 2019-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
Up to 2.8 years

What was measured

Percentage of participants with at least dose interruptions were reported.

Analysis population: The safety set included all participants who had received at least one dose of LTT462.

Groups in this outcome

LTT462 45 mg QD

Participants received 45 mg LTT462 QD as oral capsules.

LTT462 100 mg QD

Participants received 100 mg LTT462 QD as oral capsules.

LTT462 150 mg QD

Participants received 150 mg LTT462 QD as oral capsules.

LTT462 200 mg QD

Participants received 200 mg LTT462 QD as oral capsules.

LTT462 300 mg QD

Participants received 300 mg LTT462 QD as oral capsules.

LTT462 400 mg QD

Participants received 400 mg LTT462 QD as oral capsules.

LTT462 450 mg QD

Participants received 450 mg LTT462 QD as oral capsules.

LTT462 600 mg QD

Participants received 600 mg LTT462 QD as oral capsules.

LTT462 150 mg BID

Participants received 150 mg LTT462 twice daily (BID) as oral capsules.

LTT462 200 mg BID

Participants received 200 mg LTT462 BID as oral capsules.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LTT462 45 mg QD2
LTT462 100 mg QD3
LTT462 150 mg QD6
LTT462 200 mg QD4
LTT462 300 mg QD8
LTT462 400 mg QD6
LTT462 450 mg QD12
LTT462 600 mg QD6
LTT462 150 mg BID6
LTT462 200 mg BID12

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
LTT462 45 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 100 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 150 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 200 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 300 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 400 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 450 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 600 mg QD100Not reportedNot reportedNot reportedNot reported
LTT462 150 mg BID100Not reportedNot reportedNot reportedNot reported
LTT462 200 mg BID100Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        100
      2. group Id
        OG001
        value
        100
      3. group Id
        OG002
        value
        100
      4. group Id
        OG003
        value
        100
      5. group Id
        OG004
        value
        100
      6. group Id
        OG005
        value
        100
      7. group Id
        OG006
        value
        100
      8. group Id
        OG007
        value
        100
      9. group Id
        OG008
        value
        100
      10. group Id
        OG009
        value
        100
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      6
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      8
    6. group Id
      OG005
      value
      6
    7. group Id
      OG006
      value
      12
    8. group Id
      OG007
      value
      6
    9. group Id
      OG008
      value
      6
    10. group Id
      OG009
      value
      12
    units
    Participants
description
Percentage of participants with at least dose interruptions were reported.
groups
  1. description
    Participants received 45 mg LTT462 QD as oral capsules.
    id
    OG000
    title
    LTT462 45 mg QD
  2. description
    Participants received 100 mg LTT462 QD as oral capsules.
    id
    OG001
    title
    LTT462 100 mg QD
  3. description
    Participants received 150 mg LTT462 QD as oral capsules.
    id
    OG002
    title
    LTT462 150 mg QD
  4. description
    Participants received 200 mg LTT462 QD as oral capsules.
    id
    OG003
    title
    LTT462 200 mg QD
  5. description
    Participants received 300 mg LTT462 QD as oral capsules.
    id
    OG004
    title
    LTT462 300 mg QD
  6. description
    Participants received 400 mg LTT462 QD as oral capsules.
    id
    OG005
    title
    LTT462 400 mg QD
  7. description
    Participants received 450 mg LTT462 QD as oral capsules.
    id
    OG006
    title
    LTT462 450 mg QD
  8. description
    Participants received 600 mg LTT462 QD as oral capsules.
    id
    OG007
    title
    LTT462 600 mg QD
  9. description
    Participants received 150 mg LTT462 twice daily (BID) as oral capsules.
    id
    OG008
    title
    LTT462 150 mg BID
  10. description
    Participants received 200 mg LTT462 BID as oral capsules.
    id
    OG009
    title
    LTT462 200 mg BID
param Type
NUMBER
population Description
The safety set included all participants who had received at least one dose of LTT462.
reporting Status
POSTED
time Frame
Up to 2.8 years
title
Percentage of Participants With at Least One Dose Interruptions
type
PRIMARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice